

Justification for changes to Intravenous Immunoglobulin (IVIG) Demonstration Beneficiary Application

On July 25, 2014, OMB notified CMS that it had approved CMS' Intravenous Immune Globulin (IVIG) Demonstration Beneficiary Application (Form CMS-10518(7-2014)). Since that time, NHIC, the DME MAC for Jurisdiction A has served as the demonstration implementation support contractor processing all applications submitted for participation. The JA DME MAC contract was recently re-competed and awarded to Noridian. The transition from NHIC to Noridian is expected to be complete as of July 1, 2016. As a result, information that is applicable to NHIC uniquely, such as where to send the application or submit questions, needs to be revised to reflect Noridian's role as the new implementation support contractor. **Nothing on the application form regarding the information being collected is changing.** The only changes pertain to where to submit the application and/or questions and removal of references to the initial implementation enrollment period deadline. This deadline is now past and we are accepting applications on a rolling basis, so information about that date in September 2014 is no longer applicable.

Due to the limited timeframe allowed for the transition to the new DME MAC and the need to print new applications and make them available on the website, your prompt review of this request is appreciated.